Featured Intelligence

The 2020 Dichotomy: An Analysis of the COVID-19 Launch Class

May 5, 2021

The challenges of the pandemic revealed an interestingly uneven response on the commercial side, prompting the question: did biopharma’s commercial innovation keep pace with the industry’s scientific progress? Some launches showed spectacular success, while others fell far short of expectations. What were the distinguishing factors that drove this dichotomy?

Read Now

Home / Intelligence

Type
  • All
  • Briefs
  • Industry Publications
  • Scientific Publications
  • Webinars
  • Whitepaper
Search

Everything You Wanted to Know About Patient Finding but Were Afraid to Ask

According to a TGaS Advisors’ large landscape study, 45% of all machine learning commercial use cases in the life sciences industry were for finding patients, often for HCP alerts and targeting. In fact, if you are not doing patient finding alerts/targeting, you are probably behind the industry.Come join TGaS Advisors, a division of Trinity Life Sciences, as we share the “ins and outs” of patient finding, including learnings from our study. It’s clear that patient finding can have a big…

Watch now

How to Position Evidence for Successful Commercialization

The HEOR Evidence Generation team at Trinity Life Sciences will conduct a webinar to discuss recent publications geared towards crafting the value story for products prior to launch. Please join us to learn what evidence is needed and how best to position it for successful commercialization. We will present original work conducted on behalf of our valued clients in several different therapeutic areas – Oncology, Cardiology, and Rare Genetic Disorders.You already know the importance of driving awareness and conducting market…

Watch now

Agile in the Commercial Pharma Organization: Key Steps for Success

Among recent hot topics in pharma & biotech, few have been more prevalent than Agile methodologies–but what does “Agile” mean for pharma versus other industries? What are the critical Agile considerations unique to pharma, and what ad/promo, commercial operations, and compliance factors must be taken into consideration when setting up projects or pilots? During this webinar, TGaS Advisors, a division of Trinity Life Sciences, explores what commercial pharma leaders need to know when considering implementation of Agile methodologies. Driven by…

Watch now

Google’s Cookie Ban Delay Prompts Sighs of Relief, but Pharma Advertisers Shouldn’t Get Complacent

Third-party tracking cookies aren’t as important to pharma as they are to consumer marketers. Automakers, for instance, can follow online car shoppers, putting targeted digital ads in buyers’ paths as they move across the internet hoping for a sale. However, privacy policies on most sites nix drugmakers use of third-party cookies to serve ads to people looking for diabetes or cancer information. Still, tracking data does matter in pharma—especially when it comes to measurement and analytics. The good news for pharma…

Read Now

Sixty-two Percent of Biopharma Executives Say Their Organization Does Not Prioritize Diversity, Equity and Inclusion When Selecting a Vendor

Waltham, MA, July 29, 2021 — Trinity Life Sciences, a leader in global life sciences commercialization solutions, is sharing findings from its latest TGaS Advisors’ report entitled Diversity, Equity, and Inclusion (DEI): An Emerging, Key Consideration When Selecting Vendors. The report finds that 62 percent of biopharma executives say their organization does not prioritize DEI as one of the top three important reasons in selecting a vendor. However, nearly half of all respondents (48 percent) indicate that DEI has increased…

Read Now

Changes in Third-Party Cookie Management and Their Effects on Pharmaceutical Brands

The elimination of third-party cookies is not a new concept. Safari and FireFox eliminated them a few years back. However, now the largest used browser (Chrome) is joining FireFox and Safari, announcing the imminent removal of third-party cookies in 2022. Organizations are attempting to navigate the impact and identify alternatives. Driven by increased user privacy, Google’s decision will require fundamental changes across media and advertising platforms. The departure of third-party cookies will change the way pharmaceutical companies, in fact all…

Read Now

The 2020 Dichotomy: An Analysis of the COVID-19 Launch Class and How Commercial Innovation Failed…

Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…

Read Now

How Monoclonal Antibodies Can Help in the Fight Against the COVID-19 Pandemic

In this article, we aim to explain how monoclonal antibodies can help in the fight against the COVID-19 pandemic. While there are still unknowns about these drugs – such as their real-life efficacy and long-term effects, amongst others –antibodies nonetheless have the potential to effectively target several stages of the disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the overburdened health…

Read Now

Enabling the Commercial Data Environment: Five Common Pitfalls

Let’s face it, data management in the life science industry is tough regardless of the size of the company or the lifecycle of its products. For pre-commercial and emerging companies, the challenges with enabling the commercial data environment may seem insurmountable – from identifying data needs and system and process requirements to justifying resources to senior level executives and the Board to hiring the right talent and skill sets…Trinity Life Sciences has extensive experience helping pre-commercial and emerging companies establish…

Watch now

Transforming the Commercial Model in the Age of COVID-19

As the year began, we couldn’t have foreseen the unprecedented impact the COVID-19 pandemic would have on US and Global enterprises. By mid-March, we were in lock-down, and priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted. Leaders were working feverishly to enable virtual and digital channels to engage with customers as well as internal teams. Companies reached out to TGaS Advisors for our guidance in navigating this uncharted territory, and we stepped up to proactively…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.